The firm is starting a trial that it anticipates will lead to an application for marketing clearance with the US Food and Drug Administration by next year.
The startup, which was founded by two Washington University researchers and a Wharton MBA, is looking to take a big bite out of Cologuard's market.
By applying the plasmonic patch as a final step in assay development, diagnostic test developers will be able to increase fluorescence intensity onehundred-fold.
The institutes will explore the use of Inivata's liquid biopsy platform to analyze ctDNA to measure minimal residual disease in NSCLC patients.
The team developed their method to facilitate tumor cell movement through the blood-brain barrier for cancer biomarker detection. The method could eventually lead to the detection of brain cancer using a blood test.
CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.